Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026

July 17, 2026

SAN DIEGO, July 17, 2026 - Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that a Trial in Progress abstract for OP-NEU-101 has been accepted for a poster presentation at the ESMO Congress 2026, taking place October 23-27 in Madrid, Spain.

OP-NEU-101 is a Phase 1/2, first-in-human study evaluating intratumoral N17350 in patients with advanced solid tumors. N17350 is a therapeutic elastase designed to target the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while preserving immune cells.

The ESMO presentation will highlight the study's integrated translational program, which is designed to assess whether ELANE pathway engagement drives systemic anti-tumor immune response in patients. The program includes analyses of peripheral blood: serum cytokines, flow cytometry for T-cell profiling, T-cell receptor sequencing, plasma proteomics, multi-omics, and circulating tumor DNA; as well as uninjected tumor biopsies for T-cell receptor sequencing, immunohistochemistry, and proteomics to validate the ELANE pathway and T-cell driven abscopal effect.

OP-NEU-101 is enrolling in Australia and the United States. The study is evaluating the safety and tolerability of N17350, identifying a recommended Phase 2 dose, and assessing preliminary measures of clinical activity.

ESMO 2026 Presentation Details for Abstract FPN: 2041eTiP

• Title: OP-NEU-101: A phase 1/2 open-label, dose finding and expansion study to investigate the safety and effectiveness and determination of the optimal dose of N17350 administered intratumorally in participants with advanced solid tumors

• Presenter: Dr Matteo Carlino, BMedSc MBBS FRACP PhD, Department of Medical Oncology, Westmead and Blacktown Hospitals, Westmead NSW Australia

• Publication Category: Investigational immunotherapy

• Session: ePoster Session 11

• Date and Time: Friday, October 23, 1pm to 3pm CEST

• Location: Poster Area, Hall 5

About Onchilles Therapeutic Programs Targeting the ELANE Pathway

At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that leverages altered histone H1 biology, a vulnerability shared by many cancer cell types. Our pipeline is led by N17350, our first-in-class, clinical-stage program, followed by NEU-002, the second program that extends this approach with systemic delivery. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity. N17350 and NEU-002 offer a unique approach to treating cancer regardless of their genetic makeup, anatomical origin, or immune status, positioning them as potential gamechangers in cancer therapy.

About Onchilles Pharma

Onchilles Pharma is a global drug discovery and development company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. By harnessing the ELANE pathway, these next-generation therapeutics are designed to deliver potent and selective tumor cell destruction, overcoming the limitations of traditional chemotherapy and immunotherapy. The company’s pipeline includes N17350, a tumor-directed lead candidate in first-in-human studies (ClinicalTrials.gov Identifier: NCT07339176), and the NEU-002 program for systemic delivery, extends the reach of N17350 to address all solid tumors. For more information, visit www.onchillespharma.com.

Contacts

Company: Peter Haberz, Ph.D., Vice President, Corporate Development, info@onchillespharma.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com